
|Videos|March 7, 2022
Dr. Gupta on the role of immunotherapy as future standard of care for MIBC
Author(s)Urology Times staff
“I think the audience would be encouraged to know that in the future, it seems like immunotherapy would become the standard of care,” says Shilpa Gupta, MD.
Advertisement
In this video, Shilpa Gupta, MD, discusses the future research and takeaways associated with the study, “Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy,” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Gupta is the director of genitourinary oncology at Cleveland Clinic in Ohio.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Jessica Yih, MD, highlights data on testosterone therapy in women
2
Real-world data support PSA below 0.2 ng/mL as key response threshold in mCSPC
3
Higher intake of ultra-processed food associated with increased prostate cancer risk
4
Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP
5









